150
Participants
Start Date
March 31, 2002
Study Completion Date
March 31, 2005
Abacavir sulfate
Atazanavir/Ritonavir
Lopinavir/Ritonavir
Nevirapine
Beth Israel Med. Ctr., ACTU, New York
NY Univ. HIV/AIDS CRS, New York
Hosp. of the Univ. of Pennsylvania CRS, Philadelphia
Vanderbilt Therapeutics CRS, Nashville
Northwestern University CRS, Chicago
Rush Univ. Med. Ctr. ACTG CRS, Chicago
St. Louis ConnectCare, Infectious Diseases Clinic, St Louis
Washington U CRS, St Louis
University of Colorado Hospital CRS, Aurora
UCLA CARE Center CRS, Los Angeles
Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu
The Ohio State University Medical Center, Columbus
Univ. of Texas Medical Branch, ACTU, Galveston
Harbor-UCLA Med. Ctr. CRS, Torrance
Cook County Hosp. CORE Ctr., Chicago
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis
Indiana Univ. School of Medicine, Wishard Memorial, Indianapolis
Methodist Hosp. of Indiana, Indianapolis
SSTAR, Family Healthcare Ctr., Fall River
Rhode Island Hosp., Providence
Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston
University of Minnesota, ACTU, Minneapolis
Univ. of Cincinnati CRS, Cincinnati
MetroHealth CRS, Cleveland
The Miriam Hosp. ACTG CRS, Providence
National Institute of Allergy and Infectious Diseases (NIAID)
NIH